+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

LumiraDx Ltd (LMDX) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 48 Pages
  • May 2023
  • GlobalData
  • ID: 5310002
LumiraDx Ltd (LMDX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

LumiraDx Ltd (LumiraDx) is a company that provides point-of-care (PoC) diagnostic tests and solutions. The company is focused on transforming community-based healthcare by giving essential diagnostic information to healthcare practitioners at the time of need, enabling better informed medical decisions to enhance health outcomes while decreasing costs. Its product portfolio includes severe acute respiratory syndrome (SARS) coronavirus 2 (CoV-2) antigen test, SARS-CoV-2 antibody test, INR test, and D-Dimmer test. It offers solutions such as to engage, a patient program; INRstar, an anticoagulation software; and DataWell, a data-sharing solution. The company’s products are built on its proprietary, LumiraDx platform. LumiraDx is also evaluating pipeline products at various stages of development for screening infectious diseases, diabetes, and cardiovascular diseases. The company sells its products through a direct sales force and a network of distributors in the US, Europe, Japan, South Africa, Colombia, and Brazil. LumiraDx is headquartered in London, the UK.

LumiraDx Ltd Key Recent Developments

  • May 16, 2023: LumiraDx Reports First Quarter 2023 Results
  • May 09, 2023: LumiraDx to announce first quarter financial results and host quarterly conference call on May 16
  • Apr 06, 2023: LumiraDx announces strategic refocus and cost restructuring program
  • Mar 21, 2023: LumiraDx Reports Fourth Quarter and Full Year 2022 Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • LumiraDx Ltd - Key Facts
  • LumiraDx Ltd - Key Employees
  • LumiraDx Ltd - Key Employee Biographies
  • LumiraDx Ltd - Major Products and Services
  • LumiraDx Ltd - History
  • LumiraDx Ltd - Company Statement
  • LumiraDx Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • LumiraDx Ltd - Business Description
  • Geographical Segment: Colombia
  • Performance
  • Geographical Segment: Germany
  • Performance
  • Geographical Segment: Italy
  • Performance
  • Geographical Segment: Other
  • Performance
  • Geographical Segment: Sweden
  • Performance
  • Geographical Segment: United Kingdom
  • Performance
  • Geographical Segment: United States
  • Performance
  • R&D Overview
  • LumiraDx Ltd - Corporate Strategy
  • LumiraDx Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • LumiraDx Ltd - Strengths
  • LumiraDx Ltd - Weaknesses
  • LumiraDx Ltd - Opportunities
  • LumiraDx Ltd - Threats
  • LumiraDx Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • LumiraDx Ltd, Medical Equipment, Deals By Year, 2017 to YTD 2023
  • LumiraDx Ltd, Medical Equipment, Deals By Type, 2017 to YTD 2023
  • LumiraDx Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 16, 2023: LumiraDx Reports First Quarter 2023 Results
  • May 09, 2023: LumiraDx to announce first quarter financial results and host quarterly conference call on May 16
  • Apr 06, 2023: LumiraDx announces strategic refocus and cost restructuring program
  • Mar 21, 2023: LumiraDx Reports Fourth Quarter and Full Year 2022 Results
  • Mar 14, 2023: LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21
  • Nov 09, 2022: LumiraDx Reports Third Quarter 2022 Results
  • Nov 02, 2022: LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9
  • Aug 18, 2022: LumiraDx Reports Second Quarter 2022 Results
  • Aug 11, 2022: LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 18
  • May 11, 2022: LumiraDx Reports First Quarter 2022 Results
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • LumiraDx Ltd, Key Facts
  • LumiraDx Ltd, Key Employees
  • LumiraDx Ltd, Key Employee Biographies
  • LumiraDx Ltd, Major Products and Services
  • LumiraDx Ltd, History
  • LumiraDx Ltd, Subsidiaries
  • LumiraDx Ltd, Key Competitors
  • LumiraDx Ltd, Ratios based on current share price
  • LumiraDx Ltd, Annual Ratios
  • LumiraDx Ltd, Interim Ratios
  • LumiraDx Ltd, Medical Equipment, Deals By Year, 2017 to YTD 2023
  • LumiraDx Ltd, Medical Equipment, Deals By Type, 2017 to YTD 2023
  • LumiraDx Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • LumiraDx Ltd, Performance Chart (2018 - 2022)
  • LumiraDx Ltd, Ratio Charts
  • LumiraDx Ltd, Medical Equipment, Deals By Year, 2017 to YTD 2023
  • LumiraDx Ltd, Medical Equipment, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Laboratory Corporation of America Holdings - Clinical Trials Testing Division
  • Quidel Corp
  • Diagnostic Potentials Ltd
  • Becton Dickinson and Co
  • GenMark Diagnostics Inc
  • Abbott Laboratories
  • Roche Diagnostics Corp
  • Quest Diagnostics Inc
  • Danaher Corp
  • Almac Diagnostic Services Ltd
  • Siemens Healthineers AG